Ramesh Chokhani
Kathmandu
8 Papers
18 Citations
Ramesh Chokhani is an academic researcher from Kathmandu. The author has contributed to research in topics: Spirometry & Epidemiology. The author has an hindex of 2, co-authored 8 publications.
Chat about Author
Papers
Pneumococcal disease burden from an Indian perspective: Need for its prevention in pulmonology practice.
Parvaiz A Koul,Sudhir Chaudhari,Ramesh Chokhani,Devasahayam J. Christopher,Raja Dhar,Kumar Doshi,Aloke Gopal Ghoshal,S K Luhadiya,Ashok Mahashur,Ravindra L. Mehta,Amita Nene,Rahman,Rajesh Swarnakar +12 more
TL;DR: The article presents an overview of the closed-door discussion by the Indian pulmonary experts on the scientific evidence and clinical practice followed for the prevention of pneumococcal disease in India.
20
Validation of the St. George's Respiratory Questionnaire in Nepal.
Chundak T Sherpa,Steven L LeClerq,Shakuntala Singh,Neha Naithani,Raju Pangeni,Arjun Karki,Ramesh Chokhani,MeiLan K. Han,Margaret R. Gyetko,James M. Tielsch,William Checkley +10 more
TL;DR: A Nepali-validated version of SGRQ was developed, which correlated well with both disease status and severity, and was used as a screening tool to identify individuals at risk for COPD.
17
Understanding Practice Patterns of COPD: A Survey of Physicians in Nepal, Sri Lanka and Malaysia
Ramesh Chokhani,Abdul Razak Muttalif,Kirthi Gunasekera,Aniruddha Mukhopadhyay,Vaibhav Gaur,Jaideep Gogtay +5 more
- 15 Apr 2021
Abstract: There is much recent data from Nepal, Sri Lanka and Malaysia that can help us understand the practice patterns of physicians regarding the diagnosis and management of chronic obstructive pulmonary disease (COPD) in these countries. We conducted this survey to understand the practice patterns of physicians related to the diagnosis and management of COPD in these three countries. This questionnaire-based, observational, multicentre, cross-sectional survey was carried out with 438 randomly selected physicians consulting COPD patients. In the survey, 73.29% of the physicians consulted at least five COPD patients daily (all patients > 40 years of age). 31.14% of the COPD patients visiting their doctors were women. Among physicians, 95.12% reported that at least 70% of their patients were smokers. 34.18% of the physicians did not routinely use spirometry to diagnose COPD. Most physicians preferred a short-acting β2-agonist (SABA) (28.19%) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group-A and long-acting muscarinic receptor antagonist plus long-acting β2-agonist/inhaled corticosteroids (LAMA + LABA/ICS) in both the GOLD Group-C (39.86%) and Group-D (72.89%) patients. A significant number (40.67%) of physicians preferred LABA/LAMA for their GOLD Group-B patients. A pressurised metered dose inhaler (pMDI) with or without spacer was the most preferred device. Only 23.67% of the physicians believed that at least 70% of their patients had good adherence (> 80%) to therapy. Up to 54.42% of the physicians prescribed inhalation therapy to every COPD patient. Also, 39.95% of the physicians evaluated their patients’ inhalation technique on every visit. Up to 52.67% of the physicians advised home nebulisation to > 10% of patients, with nebulised SABA/short-acting muscarinic receptor antagonist (SAMA) being the most preferred management choice. Most physicians offered smoking cessation advice (94.16%) and/or vaccinations (74.30%) as non-pharmacological management, whereas pulmonary rehabilitation was offered by a smaller number of physicians. Cost of therapy and poor technique were the most common reasons for non-adherence to COPD management therapy. Awareness of spirometry can be increased to improve the diagnosis of COPD. Though physicians are following the GOLD strategy recommendations for the pharmacological and non-pharmacological management of COPD, awareness of spirometry could be increased to improve proper diagnosis. Regular device demonstration during each visit can improve the inhalation technique and can possibly increase adherence to treatment.
Allergic BronchoPulmonary Aspergillosis in Nepal
TL;DR: Allergic BronchoPulmonary Aspergillosis (ABPA) is clinically under recognized and often misdiagnosed in Nepal and patients required treatment with bronchodilator and systemic steroid.
A 40 year old woman with cough, progressive dyspnea and bilateral lung opacities
TL;DR: A 20-year-old woman had recently been orthopnic, but there was no history of wheezy breathing, and on admission she was breathless at rest and had intractable cough.